Zacks Investment Research on MSN

KYMR initiates dosing in mid-stage asthma study of lead candidate

Kymera Therapeutics KYMR announced that it has begun dosing patients in the phase IIb BREADTH study of KT-621 for moderate-to ...

Audio killing it as digital radio star soars

Forget the old Buggles hit, audio provides enormous opportunities for forward-thinking marketers, say Denstu’s Zsófi Tóth and ...